Recent Press Releases

Merck's KEYTRUDA® (pembrolizumab) Significantly Improves Survival Compared to Chemotherapy in Previously-Treated Patients with Non-Small Cell Lung Cancer Whose Tumors Express Any Level of PD-L1

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from the pivotal KEYNOTE-010 study, the first study of its kind to...

FDA Approves Expanded Indication for Merck's KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Melanoma

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded...

Skyrocketing Generic Drug Prices Cost Taxpayers $1.4 Billion, New Report Finds

Skyrocketing Generic Drug Prices Cost Taxpayers $1.4 Billion, New Report Finds WASHINGTON, Dec. 17 – Skyrocketing generic drug prices cost taxpayers an additional $1.4 billion over the last...

Sun Pharma receives Warning Letter for Halol facility

Sun Pharma receives Warning Letter for Halol facility Mumbai, December 19, 2015: Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, Sun Pharma)...

GSK's global HIV business ViiV Healthcare to acquire Bristol-Myers Squibb's R&D HIV assets

GlaxoSmithKline plc (LSE: GSK) today announced that its global HIV business, ViiV Healthcare, has reached two separate agreements with Bristol-Myers Squibb, to acquire its late-stage HIV R&D...

GSK's global HIV business ViiV Healthcare to acquire Bristol-Myers Squibb's R&D HIV assets

- Two transactions further strengthen HIV pipeline and outlook Issued: London GlaxoSmithKline plc (LSE: GSK) today announced that its global HIV business, ViiV Healthcare, has reached two separate...

Isis Pharmaceuticals Changes Name to Ionis Pharmaceuticals

Company's Shares Will Trade Under New Ticker Symbol IONS CARLSBAD, Calif., Dec. 18, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) today announced that the company has changed its...

The Medicines Company Agrees to Divest its Hemostasis Portfolio to Mallinckrodt plc

The Medicines Company (MDCO) today announced that it has entered into a purchase agreement pursuant to which certain subsidiaries of Mallinckrodt plc will acquire The Medicines Company's global...

European Commission Approves Amgen's IMLYGIC™ (talimogene laherparepvec) As First Oncolytic Immunotherapy In Europe

Pivotal Trial Showed IMLYGIC Significantly Increased Durable Response Rates in Patients With Unresectable Melanoma That is Regionally or Distantly Metastatic IMLYGIC is Approved in the European Union...

Valeant Provides Financial Guidance Update

12/16/2015 Conference Call and Webcast to be held at 8:00 am ET today LAVAL, Quebec, Dec. 16, 2015 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced...

Kadcyla price too high for routine NHS funding, says NICE in final guidance

Kadcyla price too high for routine NHS funding, says NICE in final guidance 16 December 2015 NICE has issue its final guidance on the use of Kadcyla (trastuzumab-emtansine) as a treatment for a type...

AstraZeneca to strengthen therapy area franchise through acquisition of Takeda's respiratory business

Acquisition to include non-US rights to roflumilast and will be accretive to 2016 earnings, contributing to AstraZeneca's return to growth strategy 16 December 2015 AstraZeneca today announced...

Cummings Demands Documents and Interviews From Valeant Ahead of Oversight Hearing

Washington, DC (Dec. 16, 2015)—In advance of an upcoming hearing before the House Committee on Oversight and Government Reform, Ranking Member Elijah E. Cummings sent a letter to J. Michael...

ASTRAZENECA CONTINUES STRATEGIC INVESTMENT IN CHINA TO ACCELERATE DELIVERY OF INNOVATIVE BIOLOGICS AND TARGETED MEDICINES

Strategic alliance with WuXi AppTec to develop next-generation biologics in China New small molecule development facility; new global hub for Pharmaceutical Development 16 December 2015 AstraZeneca,...

Comic Relief and GSK form five-year partnership to fight malaria and strengthen health systems

15 December 2015 Issued: London A five-year partnership to fight malaria and improve health in five countries worst affected by the disease has today been launched by Comic Relief and GSK. The two...

Amgen Reacquires All Product Rights To Prolia® (denosumab), XGEVA® (denosumab) And Vectibix® (panitumumab) From GSK In 48 Countries

Adds Product Rights and Sales in Key Global Expansion Countries THOUSAND OAKS, Calif., Dec. 14, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has entered into a definitive...

Pacira Pharmaceuticals Announces Favorable Resolution with U.S. Food and Drug Administration, which Reaffirms the Broad Indication for EXPAREL®

-- Terms Include Labeling Changes to Reinforce that the Use of EXPAREL is not Limited to Pivotal Trial Surgical Models, and Formal FDA Rescission of 2014 Warning Letter – -- Conference Call...

Merck Statement on FDA Advisory Committee Meeting on IMPROVE-IT Study with VYTORIN® (ezetimibe and simvastatin)

Merck (NYSE: MRK), known as MSD outside the United States and Canada, issued today the following statement after the conclusion of a meeting of the Endocrinologic and Metabolic Drugs Advisory...

Sanofi and Boehringer Ingelheim Enter Exclusive Negotiations on Business Swap : Sanofi Would Become a Global Leader in Consumer Healthcare and Boehringer Ingelheim Would Become Second largest Animal Health Company

Paris and Ingelheim - December 15, 2015 - Sanofi and Boehringer Ingelheim today announced that the companies have entered into exclusive negotiations to swap businesses. The proposed transaction...

FDA grants Roche's Alecensa (alectinib) accelerated approval for people with a specific type of lung cancer

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) granted accelerated approval to Alecensa® (alectinib) for the treatment of people with anaplastic...